1White RH. The epidemiology of venous thromboembolism[J]. Circulation, 2003, 107 (23suppl 1): 14-18.
2I-Io WK, Hankey GJ, Eikelboom JW. The incidence of venous thrombo-embolism:a prospective,community-based study in Perth,Western Ausstralia[J]. Med J Aust, 2008, 189(3): 144- 147.
3Bates SM, Ginsberg JS, Clinical practice.Treatment of deep- vein thrombosis[J]. N Engl J Med, 2004, 351(3): 268-277.
4Cranley JJ, Canos AJ, Sull WJ. The diagnosis of deep venous thrombosis: fallibility of clinical symptoms and signs[J]. AechSurg, 1976, 111(1): 34-36.
5Markel A, Manzo RA, Bergelin RO, et al. Valvular reflux after deep vein thrombosis: incidence and time of occurrence[J]. J Vase Surg, 1992, 15(2): 377-382.
6Anderson FA Jr, Wheeler HB, Goldberg RJ. A population- based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism:the Worcester DVT study[J]. Arch Intern Med, 1991, 151(5): 933- 938.
7Escalante CP. Causes and management of superior vena cava syndrome[J]. Oncology, 1993, 7(6): 61-68.
9Clozel JP, Bnaken L, Roux S. Aprotinin: an antidote for recombinant tissue-type plasminogen activator(rt-PA)active invivo[J]. JAm Coil Cardiol, 1990, 16(2): 507-510.
10Ay C, Pabinger I. Treatment and secondary prevention of venous thromboembolish in cancer patients.Current strategies and new therapeutic options[J]. Hamostaseologie, 2012, 32(2): 139-144.
3Jarrett B P, Dougherty M J, Galligevo K D. Infevior vena cava filters in malignant disease[J]. Vasc Surg, 2002,36 (4) : 704-707.
4Caine G J, Lip G Y, Stonelake P S, et al. Platelet activation, coagulation and angiogenesis in breast and prostate carcinomaE[J]. Thromb Haemost, 2004, 92(1):185-190.
